BIIB vs REGN
BIIB 与 REGN 的估值与基本面并排对比(公开数据)。
关键统计
| 指标 | BIIBBIOGEN INC. | REGNREGENERON PHARMACEUTICALS, INC. |
|---|---|---|
| 市值 | $30.64B | — |
| 市盈率(TTM) | 22.3 | 19.4 |
| 市净率 | 2.07 | — |
| 市销率 | 3.1x | — |
| 营收 | $9.94B(TTM) | $15.53B(TTM) |
| 营收同比增长 | 2.2% | 1.0% |
| 净利润 | $1.37B(TTM) | $4.33B(TTM) |
| 净利同比增长 | -20.8% | 2.1% |
| 每股收益(稀释) | $9.30(TTM) | $40.41(TTM) |
| 息税前利润率 | 28.7% | 24.9% |
| 净资产收益率 | 8.7% | 14.2% |
| 投入资本回报率 | 13.0% | 9.4% |
| 皮氏F值 | 4/9 | — |
| 一年总回报 | +62.5% | +39.9% |
数据来自 SEC 文件 · 仅供参考 · 非投资建议
1 万美元的成长:BIIB vs REGN
| 指标 | BIIB | REGN |
|---|---|---|
| 期末价值 | $7.4K | $18.5K |
| 总回报 | -25.9% | +85.5% |
| 年化收益 (CAGR) | -2.9% | +6.2% |
| 波动率 | 41.3% | 32.2% |
| 夏普比率 | 0.03 | 0.23 |
| 索提诺比率 | 0.05 | 0.33 |
| 最大回撤 | -72.7% | -59.7% |
基于 2600 个共同交易日,2016-04-06 → 2026-08-07 · 无风险利率 3.9%(当前短端国债,全程恒定)
A head-to-head total-return backtest over real split- and dividend-adjusted prices: how a one-time $10,000 investment in each stock, held to today, would have grown over their common window — including reinvested dividends. A disclosed historical statistic — NOT a prediction, a guarantee, or investment advice. Past performance does not predict future results.
相关对比
数据延迟 · 公开数据 · 仅供参考 · 非投资建议(本页不评判孰优孰劣)